Transformation in follicular lymphoma: Biology, prognosis, and therapeutic options

Current Oncology Reports

Volumn 14, Issue 5, 2012, Pages 424-432

  Wong, Eric ^a   Dickinson, Michael ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Follicular lymphoma; Non Hodgkin lymphoma; Stem cell transplantation; Transformation

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BETA 2 MICROGLOBULIN; CARBOPLATIN; CARMUSTINE; CD4 ANTIGEN; CD69 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; HLA ANTIGEN; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; LACTATE DEHYDROGENASE; MELPHALAN; PREDNISOLONE; PURINE DERIVATIVE; RITUXIMAB; TOSITUMOMAB I 131; TRANSCRIPTION FACTOR FOXP3; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BCL6 GENE; BURKITT LYMPHOMA; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CD4+ T LYMPHOCYTE; CDK2A GENE; FOLLICULAR LYMPHOMA; GENE MUTATION; GENETIC ASSOCIATION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; MALIGNANT TRANSFORMATION; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; ONCOGENE MYC; OVERALL SURVIVAL; PAX5 GENE; PHASE 3 CLINICAL TRIAL (TOPIC); PIM1 GENE; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROTO ONCOGENE; REL GENE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; WATCHFUL WAITING; WHOLE BODY RADIATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84870495308     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0258-4     Document Type: Article

References (51)

1. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984;311 (23):1471-5.
2. Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(32):5165-9.
3. Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997;15 (4):1587-94.
4. Conconi A, Ponzio C, Lobetti-Bodoni C, Motta M, Rancoita PMV, Stathis A et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol. 2012;157 (2):188-96.
5. Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25(17):2426-33.
6. Garvin AJ, Simon RM, Osborne CK, Merrill J, Young RC, Berard CW. An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute. Cancer. 1983;52(3):393-8.
7. Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(21):4643-51.
8. Bodet-Milin C, Kraeber-Bodéré F, Moreau P, Campion L, Dupas B, Le Gouill S. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica. 2008;93(3):471-2.
9. Noy A, Schöder H, Gönen M, Weissler M, Ertelt K, Cohler C et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol. 2009;20(3):508-12. Described the utility of standardised uptake values in identifying transformed lymphoma.
10. Giné E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol. 2006;17(10):1539-45.
11. Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial. Lancet. 2003;362(9383):516-22.
12. Sinha R, Byrtek M, De Joubner N, Nooka A, Taylor M, Cerhan J, et al. Examining the outcomes of watchful waiting among US patients with advanced stage follicular lymphoma [abstract 775]. American Society of Haematology Conference 2011.
13. Cohen Y, Daas N, Libster D, Amir G, Berrebi A, Polliack A. Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: Natural history-or therapy-related complication? Eur J Haematol. 2002;68(2):80-3.
14. Matolcsy A, Schattner EJ, Knowles DM, Casali P. Clonal evolution of B cells in transformation from low-to high-grade lymphoma. Eur J Immunol. 1999;29(4):1253-64.
15. Rossi D, Berra E, Cerri M, Deambrogi C, Barbieri C, Franceschetti S, et al. Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma. Haematologica. 2006;91(10):1405-9.
16. Davies AJ, Rosenwald A,Wright G, Lee A, Last KW,Weisenburger DD, et al. Transformation of follicular lymphoma to diffuse large Bcell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol. 2007;136(2):286-93.
17. Gentles AJ, Alizadeh AA, Lee S-I, Myklebust JH, Shachaf CM, Shahbaba B, et al. A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood. 2009;114(15):3158- 66.
18. Symmans WF, Katz RL, Ordoñez NG, Dalton H, Romaguera JE, Cabanillas F. Transformation of follicular lymphoma. Expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation. Acta Cytol. 1995;39(4):673-82.
19. Szereday Z, Csernus B, Nagy M, László T, Warnke RA, Matolcsy A. Somatic mutation of the 5' noncoding region of the BCL-6 gene is associated with intraclonal diversity and clonal selection in histological transformation of follicular lymphoma. Am J Pathol. 2000;156(3):1017-24.
20. Carlotti E, Wrench D, Matthews J, Iqbal S, Davies A, Norton A, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood. 2009;113(15):3553-7.
21. Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, et al. Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood. 2010;116(9):1489-97.
22. Martinez A, Carreras J, Campo E. The follicular lymphoma microenvironment: From tumor cell to host immunity. Curr Hematol Malignancy Rep. 2008;3(4):179-86.
23. Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE, Wessels LA, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol. 2007;25 (4):390-8.
24. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108(9):2957-64.
25. Skibola CF, Bracci PM, Halperin E, Conde L, Craig DW, Agana L, et al. Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet. 2009;41(8):873-5.
26. Akers NK, Curry JD, Conde L, Bracci PM, Smith MT, Skibola CF. Association of HLA-DQB1 alleles with risk of follicular lymphoma. Leuk Lymphoma. 2011;52(1):53-8.
27. Wrench D, Leighton P, Skibola CF, Conde L, Cazier J-B, Matthews J, et al. SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma. Blood. 2011;117(11):3147-50.
28. Al-Tourah AJ, Savage KJ, Gill KK, Klasa RJ, Sehn LH, Shenkier TN, et al. Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. ASH Annu Meet Abstr. 2007;110(11):790.
29. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ Bcell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17(12):3793-803.
30. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, et al. Iodine-131-anti-B1 radioimmunotherapy for Bcell lymphoma. J Clin Oncol. 1996;14(7):1974-81.
31. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20(10):2453-63.
32. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19 (19):3918-28.
33. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23(30):7565-73.
34. Andreadis C, Schuster SJ, Chong EA, Svoboda J, Luger SM, Porter DL, et al. Long-term event-free survivors after highdose therapy and autologous stem-cell transplantation for lowgrade follicular lymphoma. Bone Marrow Transplant. 2005;36 (11):955-61.
35. Chen CI, CrumpM, Tsang R, Stewart AK,Keating A. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haematol. 2001;113(1):202-8.
36. Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M et al. High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. Br J Haematol. 2011;152(5):600-10. The only prospective study of high dose chemotherapy with ASCT in transformed lymphoma.
37. Hamadani M, Benson DM, Lin TS, Porcu P, Blum KA, Devine SM. High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Eur J Haematol. 2008;81(6):425-31.
38. Sabloff M, Atkins HL, Bence-Bruckler I, Bredeson C, Fergusson D, Genest P, et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant. 2007;13(8):956-64.
39. Williams CD, Harrison CN, Lister TA, Norton AJ, Blystad AK, Coiffier B, et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: A case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol. 2001;19(3):727-35.
40. Villa KS D, Crump M, Toze C, Rubinger M, Lee C, Alzahrani M, et al. "Focus on " session: High-dose chemotherapy. Ann Oncol. 2011;22 suppl 4:iv115-6.
41. Ban-Hoefen M, Kelly JL, Bernstein SH, Liesveld J, Constine L, Becker M et al. High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma. 2012;53(5):830-5. A retrospective analysis of ASCT in transformed lymphoma in patients previously exposed to rituximab.
42. Ramadan KM, Connors JM, Al-Tourah AJ, Song KW, Gascoyne RD, Barnett MJ, et al. Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: Longterm results. Bone Marrow Transplant. 2008;42(9):601-8.
43. Ghesquières H, Berger F, Felman P, Callet-Bauchu E, Bryon P-A, Traverse-Glehen A, et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol. 2006;24(33):5234-41.
44. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol. 2005;131(2):223-30.
45. Villa. Lugano ASCT transformed lymphoma. Ann Oncol. 2011;22 (Supplement 4):iv10-24.
46. Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(2):211-7.
47. Clavert A, Le Gouill S, Brissot E, Dubruille V, Mahe B, Gastinne T, et al. Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51(8):1502-8.
48. Hamadani M, Benson DM, Hofmeister CC, Elder P, Blum W, Porcu P, et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant. 2009;15(5):547-53.
49. Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, et al. Rituximab purging and maintenance improves progression free survival but not overall survival in patients with relapsed or resistant follicular lymphoma prior receiving an autologous transplant. ASH Annu Meet Abstr. 2010;116 (21):3567.
50. Czuczman MS, Vose JM, Witzig TE, Zinzani PL, Buckstein R, Polikoff J, et al. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. Br J Haematol. 2011;154 (4):477-81.
51. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22(7):1622-7.